Altrincham biopharmaceutical firm Sling Therapeutics UK Limited files new share allotment

Developing an oral small molecule therapy for thyroid eye disease is the primary focus of Altrincham-based Sling Therapeutics UK Limited. The biopharmaceutical company is currently engaged in the late-stage development of linsitinib, a treatment designed for patients suffering from the autoimmune condition. Thyroid eye disease primarily affects women and causes significant inflammation and swelling in the tissues behind the eye.

The company recently filed documentation for a new allotment of shares (allotment date March, filing date May). While the specific amount of capital raised and the resulting valuation were not disclosed in the filing, the transaction follows the company's incorporation in March.

Ryan Khalil Zeidan was appointed to the board of directors in March. The company's financial reporting cycle is established with a year end of 31 December 2026. As a recently incorporated development-stage entity, the firm has not yet published figures for revenue, total assets, or profit and loss.

The therapy, linsitinib, is an oral small molecule designed to inhibit specific pathways involved in the progression of the disease. By offering an oral alternative, the company seeks to improve patient accessibility compared to existing treatment methods. Sling Therapeutics UK Limited operates as a research and development business.

The condition the company targets can lead to symptoms such as eye bulging, double vision, and potential vision loss. The Altrincham office serves as the base for these development efforts as the company moves through the late-stage clinical process.